Trial Profile

A pivotal phase IIb/III trial of WT1 vaccine in patients with malignant pleural mesothelioma

Status: Planning

Phase of Trial: Phase II/III

Latest Information Update: 25 Sep 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Galinpepimut S (Primary)
Indications Malignant-mesothelioma
Focus Registrational; Therapeutic Use
Sponsors Sellas Life Sciences Group

Most Recent Events

14 Sep 2016 According to Sellas Life Sciences Group media release, this trial is expected to start in early 2017.
14 Sep 2016 Planned initiation date changed from 1 Jul 2016 to 1 Jan 2017, as per Sellas Life Sciences Group media release.
29 Mar 2016 According to SELLAS Life Sciences media release, based on results of phase II trial (see CTP 700192768), the company plans to initiate this pivotal trial of WT1 peptide vaccine in patients with MPM, in the third quarter of 2016.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com